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We would like to thank Dr Takagi et al for their thoughtful
meta-analytic response to our article on the effect of statins in
patients undergoing lower extremity bypass surgery for critical
limb ischemia. As Dr Takagi points out in his letter to the editor,
our data demonstrated that statins had a definitive survival benefit
at one year. However, we were unable to show a statistically
significant effect on 30-day perioperative survival. In addressing
this finding (or lack therof), we noted in our discussion that “. . .
the negative findings for perioperative . . . events in this study must
be interpreted with great caution [because] this study may have
lacked statistical power to demonstrate certain associations.” In
other words, we were concerned that the absence of a significant
30-day survival benefit was attributable to a type II statistical error.
The metanalysis by Dr. Takagi and colleagues lends additional
support to our conviction that statins are beneficial in patients with
critical limb ischemia, not only in the long-term, but most likely, in
the short-term as well. We congratulate Dr Takagi et al on their
analyses and thank them for their comments.
Andres Schanzer, MD
Division of Vascular and Endovascular Surgery
University of Massachusetts Medical School
Worcester, Mass
doi:10.1016/j.jvs.2009.01.015
Regarding “The benefit of statins in non-cardiac
vascular surgery patients”
The excellent article by Stalenhoef reviews the benefits of
statins in non-cardiac vascular surgery patients.1 Some additional
comments may be of interest.
Preliminary evidence from observational studies suggests that
statins may suppress the development of abdominal aortic aneu-
rysms (AAAs).2 Verification of these positive results in randomized
controlled trials holds implications for the medical management of
AAAs.3 This may be particularly important for those patients who
are very elderly and/or unfit-to-undergo surgery/endovascular
AAA repair.
Other possible beneficial effects of statin use in vascular pa-
tients undergoing surgery include reductions in postoperative
infections and intra-abdominal adhesions.4 These effects, however,
also need to be verified in randomized controlled trials.
The beneficial effects of statins may not apply to all vascular
patients. For example, although routine statin use at around
$250.00/year is cost-effective for AAA patients,2 this may not be
true for asymptomatic individuals with mild subclinical carotid
atherosclerosis.5 Statins may improve perioperative outcomes in
patients undergoing non-cardiac vascular surgery;1,6 however,
their use in early stages of vascular disease may be neither efficient
nor cost-effective.
Although it is true that “statins have become, beyond a doubt,
an essential instrument in the management of the vascular pa-
tient,”1 the optimal dosage, exact indications, and timing for
initiation of statin treatment in vascular surgery patients remain to
be defined.Kosmas I. Paraskevas, MD, FASA
Department of Vascular Surgery
Red Cross Hospital
Athens, Greece
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Reply
The purpose of this first article in the new evidence-based
review series in the Journal was to review the evidence that statins
are directly beneficial in preventing the progression of atheroscle-
rotic disease in other parts of the vascular tree than the coronaries
as well as their effect on perioperative outcomes in vascular surgery
patients.1 Studies that examine the effect of statins on peripheral
arterial disease are mostly observational in nature and subject to
confounding (with the exception of the Heart Protection Study2).
The effect of statins on perioperative outcomes is also inconclu-
sive.1 I agree with Dr Paraskevas that the optimal dose, exact
indications, and timing for initiation of statin treatment in vascular
surgery patients remain to be determined, although it may not be
possible to conduct randomized trials.
Anton F. Stalenhoef, MD, PhD, FRCP
Department of Medicine
Radboud University Nijmegen Medical Centre
Nijmegen, The Netherlands
REFERENCES
1. Stalenhoef AF. The benefit of statins in non-cardiac vascular surgery
patients. J Vasc Surg 2009;49:260-5.
2. Heart Protection Study Group. Randomized trial of the effects of
cholesterol-lowering with simvastatin on peripheral vascular and other
major vascular outcomes in 20,536 people with peripheral arterial
disease and other high-risk conditions. J Vasc Surg 2007;45:645-54.doi:10.1016/j.jvs.2009.02.210
